Results of a Multicenter Prospective Observational Study “ALLIANCE” on the Impact of Rifaximin and Trimebutine on Quality of Life and the Course of Uncomplicated Diverticular Disease in Outpatient Clinical Practice
Authors:
- V. T. IvashkinVIV. T. Ivashkin
- E. A. PoluektovaEPE. A. Poluektova
- O. S. ShifrinOSO. S. Shifrin
- A. S. TrukhmanovATA. S. Trukhmanov
- Z. A. MamievaZMZ. A. Mamieva
- R. V. MaslennikovRMR. V. Maslennikov
- S. М. BabinaSBS. М. Babina
- O. Yu. BaryshevaOBO. Yu. Barysheva
- I. V. GuboninaIGI. V. Gubonina
- E. N. SmirnovaESE. N. Smirnova
- S. E. El KhaekSKS. E. El Khaek
Open Access
- 7 October 2025
- journal article
- Published by Russian Gastroenterolgocial Society in Russian Journal of Gastroenterology, Hepatology, Coloproctology
- Vol. 35 (4) , 88-97
Abstract
Aim: to evaluate the impact of the drugs Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) on symptom severity and quality of life in patients with uncomplicated diverticular disease.Materials and methods. A multicenter non-interventional prospective observational study was conducted, involving 100 patients diagnosed with uncomplicated diverticular disease. Patients received Alfaxim® (rifaximin) at 400 mg 2–3 times daily for 7 days monthly over 6 months and Neobutin Retard® (trimebutine) at 300 mg twice daily for 4 weeks, in addition to standard therapy. Symptom severity (abdominal pain, constipation, diarrhea, bloating, tenesmus) was assessed using a 3-point scale. Quality of life was evaluated using the SF-12 questionnaire. Patient adherence to treatment was measured using the Morisky — Green Compliance Scale.Results. Cyclic therapy with Alfaxim® and Neobutin Retard® showed statistically significant (p < 0.001) positive effects on all assessed symptoms. Over half of the patients (55 %) achieved remission by the end of the observation period. Analysis of SF-12 scores revealed a significant improvement in quality of life (p < 0.001). Most patients demonstrated high treatment adherence throughout the study. No adverse events were recorded during the observation period.Conclusions. The use of Alfaxim® (rifaximin) and Neobutin Retard® (trimebutine) reduces symptom severity and improves quality of life in patients with uncomplicated diverticular disease. The drugs have a favorable safety profile.Keywords
This publication has 14 references indexed in Scilit:
- Gas‐Related Symptoms in the General Population: Prevalence, Impact and Associated Factors in a Survey of the United States, the United Kingdom, and MexicoNeurogastroenterology & Motility, 2025
- Diverticular disease: update on pathophysiology, classification and managementFrontline Gastroenterology, 2023
- Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative reviewTherapeutic Advances in Gastroenterology, 2020
- Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colonJournal of Investigative Medicine, 2019
- Acute Lower Gastrointestinal BleedingNew England Journal of Medicine, 2017
- Probiotics in the Treatment of Diverticular Disease. A Systematic ReviewJournal of Gastrointestinal and Liver Diseases, 2016
- Review article: the antimicrobial effects of rifaximin on the gut microbiotaAlimentary Pharmacology & Therapeutics, 2015
- Meta-analysis: long-term therapy with rifaximin in the management of uncomplicated diverticular diseaseAlimentary Pharmacology & Therapeutics, 2011
- A 12-Item Short-Form Health SurveyMedical Care, 1996
- Concurrent and Predictive Validity of a Self-reported Measure of Medication AdherenceMedical Care, 1986